Crestline Management, LP Beam Therapeutics Inc. Transaction History
Crestline Management, LP
- $2.93 Billion
- Q4 2024
A detailed history of Crestline Management, LP transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Crestline Management, LP holds 62,969 shares of BEAM stock, worth $1.64 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
62,969
Previous 17,415
261.58%
Holding current value
$1.64 Million
Previous $426,000
266.43%
% of portfolio
0.05%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding BEAM
# of Institutions
253Shares Held
78.6MCall Options Held
304KPut Options Held
142K-
Farallon Capital Management LLC San Francisco, CA8.24MShares$215 Million1.09% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$199 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$199 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$185 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.54MShares$119 Million70.85% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.84B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...